Free Newsletter
International troika drives biomanufacturing platforms
GE Healthcare has teamed with Sweden's iBio and the Fraunhofer Center for Molecular Biotechnology to develop biopharma and vaccine manufacturing gear. The arrangement capitalizes on GE's global life sciences muscle, the iBioLaunch plant-based vaccine and therapeutic protein manufacturing platform, and Fraunhofer's vaccine and molecular biology expertise. GE will supply bioprocessing products and process expertise for integration with the iBioLaunch platform. It will also support the development of products based on the iBioLaunch platform and product offering. iBio release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: